Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Metacrine, Inc. (MTCR) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/15/2023 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
02/09/2023 8-K Entry into a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
02/03/2023 8-K Quarterly results
02/01/2023 8-K Quarterly results
01/24/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Plan of Dissolution of Metacrine, Inc",
"Separation Agreement and General Release of All Claims, by and between Metacrine, Inc. and Preston Klassen"
10/11/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
09/06/2022 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Agreement and Plan of Merger, by and among Equillium, Inc., Metacrine, Inc., Equillium Acquisition Sub, Inc., and Triumph Merger Sub, Inc",
"Equillium to Acquire Metacrine in All-Stock Transaction",
"Investor Presentation"
08/09/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "METACRINE REPORTS SECOND-QUARTER 2022 RESULTS"
08/05/2022 8-K Quarterly results
05/18/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/06/2022 8-K Termination of a Material Definitive Agreement  Interactive Data
03/30/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "METACRINE REPORTS FOURTH-QUARTER 2021 RESULTS"
03/15/2022 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Agreement for Termination of Lease and Voluntary Surrender of Premises, by and between Metacrine, Inc. and ARE-SD Region No. 30, LLC",
"Agreement for Termination of Lease and Voluntary Surrender of Premises, by and between Metacrine, Inc. and ARE-SD Region No. 30, LLC"
03/03/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
02/11/2022 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Departure of Directors or Ce...
Docs: "METACRINE UPDATES IBD CLINICAL DEVELOPMENT STRATEGY AND IMPLEMENTS RESTRUCTURING PLAN"
02/10/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
01/28/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation and Consulting Agreement, between Metacrine, Inc. and Catherine Lee"
12/27/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "METACRINE ANNOUNCES RESIGNATION OF CHIEF MEDICAL OFFICER"
11/12/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "METACRINE REPORTS THIRD-QUARTER 2021 RESULTS"
11/02/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "METACRINE REPORTS TOPLINE RESULTS FOR MET409 PHASE 2A COMBINATION TRIAL IN PATIENTS WITH TYPE 2 DIABETES AND NASH"
10/21/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "METACRINE REPORTS INTERIM RESULTS FOR MET642 PHASE 2A TRIAL IN PATIENTS WITH NASH AND ANNOUNCES A STRATEGIC RE-PRIORITIZATION OF ITS CLINICAL DEVELOPMENT PROGRAMS"
10/04/2021 8-K Quarterly results
09/15/2021 8-K Quarterly results
08/12/2021 8-K Quarterly results
05/26/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
04/05/2021 8-K Quarterly results
03/18/2021 8-K Quarterly results
02/12/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "New MET409 Data to be Presented at AASLD’s The Liver Meeting Digital Experience: Two posters highlighting pharmacokinetic and pharmacodynamic data along with early prediction of longer term changes in liver fat content on the company’s lead clinical candidate, MET409, a farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis , will be presented at the American Association for the Study of Liver Diseases’ The Liver Meeting Digital Experience™. The virtual meeting is taking place November 13-16, 2020. • SGLT-2 Inhibitor Selected as Combination Agent for MET409 Phase 2a Combination Trial: Metacrine has selected empagliflozina sodium-glucose cotransport-2 inhibitor, to be evaluated in combination with MET409 in the company’s planned Phase 2a clinical trial ..."
09/18/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Docs: "Amended and Restated Certificate of Incorporation of the Company",
"Amended and Restated Bylaws of the Company"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy